Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

March 23, 2023

Julie Renee Brahmer, MD, discusses the use of tremelimumab plus durvalumab and platinum-based chemotherapy for the first-line treatment of patients with non–small cell lung cancer, and how decisions can be made between this regimen and nivolumab plus ipilimumab and chemotherapy.

March 16, 2023

Jean Wright, MD, discusses the benefit of moderate hypofractionation in patients for adjuvant radiotherapy in patients with early-stage breast cancer.

March 16, 2023

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

March 16, 2023

The combination of nivolumab and relatlimab demonstrated clinical benefit with a manageable safety profile in patients with advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression, according to findings from the ongoing phase 1/2a RELATIVITY-020 trial.

March 08, 2023

Julie Renee Brahmer, MD, discusses clinical trials investigating treatment options for patients with non–small cell lung cancer following progression after first-line immunotherapy.

March 06, 2023

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

February 28, 2023

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.

February 27, 2023

Tania Jain, MBBS, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors in myelofibrosis.

February 24, 2023

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.

February 24, 2023

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

February 24, 2023

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

February 16, 2023

Haploidentical donors and posttransplant cyclophosphamide is a comparable alternative to matched unrelated donors for patients with myelofibrosis receiving blood or marrow transplant without matched sibling donors, although matched sibling donors, when available, remain the preferred donor option.

February 15, 2023

Treatment with neoadjuvant nivolumab led to encouraging 5-year recurrence-free survival and overall survival rates compared with historical outcomes in patients with non–small cell lung cancer who underwent surgical resection.

January 12, 2023

Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.

January 11, 2023

Alexander Spira, MD, PhD, FACP, highlights the top advancements across non–small cell lung cancer in 2022, emphasized the need for increased genetic testing to inform treatment decisions, and previewed other agents under development.

December 01, 2022

Evan J. Lipson, MD, expands on key takeaways from the NEOpredict-Lung trial, the additional benefit that PICIT may offer to patients who progress on other immunotherapies, and the effect that both NEOpredict-Lung and RELATIVITY-047 have on the role of immunotherapy in the lung and melanoma treatment paradigms.

November 28, 2022

Benjamin P. Levy, MD; Bhuvana Ramkumar, MD; and Neil Morganstein, MD, discuss the challenges with tissue testing facing care teams, as well as multilevel hurdles in procurement, analysis of results, and insurance.

November 14, 2022

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

November 11, 2022

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

October 21, 2022

Kara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.